Tissue Regenix Group PLC
TRX
Company Profile
Business description
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
Contact
Lotherton Way
Unit 3, Phoenix Court
GarforthLS25 2GY
GBRT: +44 3304303052
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
82
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,543.70 | 34.10 | -0.40% |
| CAC 40 | 7,497.52 | 7.24 | 0.10% |
| DAX 40 | 20,370.72 | 53.62 | 0.26% |
| Dow JONES (US) | 42,635.20 | 106.84 | 0.25% |
| FTSE 100 | 8,298.56 | 21.13 | -0.25% |
| HKSE | 19,064.29 | 176.60 | -0.92% |
| NASDAQ | 19,478.88 | 10.80 | -0.06% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,895.98 | 47.76 | -0.37% |
| S&P 500 | 5,918.25 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,294.10 | 35.10 | -0.42% |
| SSE Composite Index | 3,168.52 | 42.87 | -1.33% |